Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined
Background Endothelial dysfunction is an early event in atherosclerotic disease that precedes clinical manifestations and complications. The noninvasive assessment of endothelial function in patients with risk factors undergoing clinical treatment is an important medical advance. In this setting, al...
Gespeichert in:
Veröffentlicht in: | The American heart journal 2000-10, Vol.140 (4), p.684-689 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 689 |
---|---|
container_issue | 4 |
container_start_page | 684 |
container_title | The American heart journal |
container_volume | 140 |
creator | Esper, Ricardo J. Machado, Rogelio Vilariño, Jorge Cacharrón, José L. Ingino, Carlos A. Garcı́a Guiñazú, Carlos A. Bereziuk, Eulalio Bolaño, Alberto L. Suarez, Daniel H. |
description | Background Endothelial dysfunction is an early event in atherosclerotic disease that precedes clinical manifestations and complications. The noninvasive assessment of endothelial function in patients with risk factors undergoing clinical treatment is an important medical advance. In this setting, altered endothelial function in patients with coronary hypercholesterolemia and its modifications by treatment with enalapril and simvastatin, either separately or in combination, was assessed in the brachial artery in a randomized, double-blind, 2-period crossover study. Methods Thirty-eight patients were separated in 2 groups. Group 1 (18 patients, 3 female, mean age 63 ± 6.0 years) received simvastatin 10 mg/d for 8 weeks and simvastatin plus enalapril 5 mg/d for another 8 weeks. Group 2 (20 patients, 3 female, mean age 64 ± 5.8 years) received enalapril 5 mg/d for 8 weeks and enalapril plus simvastatin 10 mg/d for another 8 weeks. All subjects underwent measurements of brachial artery diameter before and after postischemic hyperemia with high-resolution ultrasound at basal conditions (control) and under the effects of the drugs at the end of 8 and 16 weeks. Results Cholesterol and LDL cholesterol levels significantly decreased with simvastatin treatment alone or with enalapril. Mean baseline arterial diameter was 5.24 ± 1.25 mm in group 1 and 4.83 ± 0.99 mm in group 2 (not significant). In group 1 after the first 8 weeks, endothelium-dependent vasodilation significantly increased with simvastatin treatment (control, 4.4%; 8 weeks, 7.6%; P < .001). After 16 weeks with the addition of enalapril, a further increase in vasodilation was seen (8.6%, P < .05 vs 8 weeks). In group 2, with enalapril treatment an increase in vasodilation versus control was seen (control, 4.3%; 8 weeks, 5.8%; P < .01). After 16 weeks, with the addition of simvastatin an additional increase in vasodilation was observed (9.1%, P < .001 vs 8 weeks). After nitroglycerin, vasodilation in group 1 at control, 8, and 16 weeks was 17%, 17.5%, and 18%, respectively. In group 2, nitroglycerin vasodilation at control, 8, and 16 weeks was 21%, 21%, and 22%, respectively. Conclusions Simvastatin significantly increased the postischemic vasodilator response in patients with coronary hypercholesterolemia, either as single treatment or added to enalapril. Similarly, the response was increased by enalapril, either alone or while simvastatin was being administered. Both drugs improve vasodilation and addit |
doi_str_mv | 10.1067/mhj.2000.109649 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72304608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870300163422</els_id><sourcerecordid>72304608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-6b9413c2c367b14b0b8090c09df7134aa377a61dd255f842f9f3ccecb45ceb883</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EotvCmRuyhMSpae3EGydHVJUPqRIXOFuOPVZcJXbwJEX7m_onmdWu4MRpPONnXnvmZeydFDdStPp2Hh9vaiGOWd-q_gXb0UFXrVbqJdvRRV11WjQX7BLxkdK27trX7EJKIWWj2h17vk8-ryNMcZsrDwskD2nlBXDJCQF5THyxa6Qi8t9xHfl4WKC4MU-AKxQKc3Tc5ZKTLQduCxUP3EcEi8A3kiuc9DmEAI40cuAY5yeLK6kmbpPnkOxklxKnaw70AjUgLLbYFaYDz4XE5yEm8G_Yq2AnhLfneMV-fr7_cfe1evj-5dvdp4fKNVquVTv0Sjaudk2rB6kGMXSiF070Pmga2tpGa9tK7-v9PnSqDn1onAM3qL2DoeuaK_bxpLuU_GujMc0c0cE02QR5Q6PrRqhWHMHbE-hKRiwQDE0x0xqMFObojyF_zNEfc_KHOt6fpbdhBv-PPxtCwIczYNHZKRSbXMS_nO76faeI6k8U0BqeIhSDjixy4GOhLRuf43-_8Ac24bEO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72304608</pqid></control><display><type>article</type><title>Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Esper, Ricardo J. ; Machado, Rogelio ; Vilariño, Jorge ; Cacharrón, José L. ; Ingino, Carlos A. ; Garcı́a Guiñazú, Carlos A. ; Bereziuk, Eulalio ; Bolaño, Alberto L. ; Suarez, Daniel H.</creator><creatorcontrib>Esper, Ricardo J. ; Machado, Rogelio ; Vilariño, Jorge ; Cacharrón, José L. ; Ingino, Carlos A. ; Garcı́a Guiñazú, Carlos A. ; Bereziuk, Eulalio ; Bolaño, Alberto L. ; Suarez, Daniel H.</creatorcontrib><description>Background Endothelial dysfunction is an early event in atherosclerotic disease that precedes clinical manifestations and complications. The noninvasive assessment of endothelial function in patients with risk factors undergoing clinical treatment is an important medical advance. In this setting, altered endothelial function in patients with coronary hypercholesterolemia and its modifications by treatment with enalapril and simvastatin, either separately or in combination, was assessed in the brachial artery in a randomized, double-blind, 2-period crossover study. Methods Thirty-eight patients were separated in 2 groups. Group 1 (18 patients, 3 female, mean age 63 ± 6.0 years) received simvastatin 10 mg/d for 8 weeks and simvastatin plus enalapril 5 mg/d for another 8 weeks. Group 2 (20 patients, 3 female, mean age 64 ± 5.8 years) received enalapril 5 mg/d for 8 weeks and enalapril plus simvastatin 10 mg/d for another 8 weeks. All subjects underwent measurements of brachial artery diameter before and after postischemic hyperemia with high-resolution ultrasound at basal conditions (control) and under the effects of the drugs at the end of 8 and 16 weeks. Results Cholesterol and LDL cholesterol levels significantly decreased with simvastatin treatment alone or with enalapril. Mean baseline arterial diameter was 5.24 ± 1.25 mm in group 1 and 4.83 ± 0.99 mm in group 2 (not significant). In group 1 after the first 8 weeks, endothelium-dependent vasodilation significantly increased with simvastatin treatment (control, 4.4%; 8 weeks, 7.6%; P < .001). After 16 weeks with the addition of enalapril, a further increase in vasodilation was seen (8.6%, P < .05 vs 8 weeks). In group 2, with enalapril treatment an increase in vasodilation versus control was seen (control, 4.3%; 8 weeks, 5.8%; P < .01). After 16 weeks, with the addition of simvastatin an additional increase in vasodilation was observed (9.1%, P < .001 vs 8 weeks). After nitroglycerin, vasodilation in group 1 at control, 8, and 16 weeks was 17%, 17.5%, and 18%, respectively. In group 2, nitroglycerin vasodilation at control, 8, and 16 weeks was 21%, 21%, and 22%, respectively. Conclusions Simvastatin significantly increased the postischemic vasodilator response in patients with coronary hypercholesterolemia, either as single treatment or added to enalapril. Similarly, the response was increased by enalapril, either alone or while simvastatin was being administered. Both drugs improve vasodilation and additive effects appear to be present. (Am Heart J 2000;140:684-9.)</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1067/mhj.2000.109649</identifier><identifier>PMID: 11011346</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Biological and medical sciences ; Brachial Artery - diagnostic imaging ; Brachial Artery - drug effects ; Brachial Artery - physiopathology ; Cardiovascular system ; Cholesterol - blood ; Coronary Disease - blood ; Coronary Disease - drug therapy ; Coronary Disease - physiopathology ; Cross-Over Studies ; Double-Blind Method ; Drug Therapy, Combination ; Enalapril - therapeutic use ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - blood ; Hypercholesterolemia - drug therapy ; Hypercholesterolemia - physiopathology ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Pharmacology. Drug treatments ; Simvastatin - therapeutic use ; Tropical medicine ; Ultrasonography ; Vasodilation - drug effects</subject><ispartof>The American heart journal, 2000-10, Vol.140 (4), p.684-689</ispartof><rights>2000 Academic Press</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-6b9413c2c367b14b0b8090c09df7134aa377a61dd255f842f9f3ccecb45ceb883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1067/mhj.2000.109649$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=789584$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11011346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Esper, Ricardo J.</creatorcontrib><creatorcontrib>Machado, Rogelio</creatorcontrib><creatorcontrib>Vilariño, Jorge</creatorcontrib><creatorcontrib>Cacharrón, José L.</creatorcontrib><creatorcontrib>Ingino, Carlos A.</creatorcontrib><creatorcontrib>Garcı́a Guiñazú, Carlos A.</creatorcontrib><creatorcontrib>Bereziuk, Eulalio</creatorcontrib><creatorcontrib>Bolaño, Alberto L.</creatorcontrib><creatorcontrib>Suarez, Daniel H.</creatorcontrib><title>Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background Endothelial dysfunction is an early event in atherosclerotic disease that precedes clinical manifestations and complications. The noninvasive assessment of endothelial function in patients with risk factors undergoing clinical treatment is an important medical advance. In this setting, altered endothelial function in patients with coronary hypercholesterolemia and its modifications by treatment with enalapril and simvastatin, either separately or in combination, was assessed in the brachial artery in a randomized, double-blind, 2-period crossover study. Methods Thirty-eight patients were separated in 2 groups. Group 1 (18 patients, 3 female, mean age 63 ± 6.0 years) received simvastatin 10 mg/d for 8 weeks and simvastatin plus enalapril 5 mg/d for another 8 weeks. Group 2 (20 patients, 3 female, mean age 64 ± 5.8 years) received enalapril 5 mg/d for 8 weeks and enalapril plus simvastatin 10 mg/d for another 8 weeks. All subjects underwent measurements of brachial artery diameter before and after postischemic hyperemia with high-resolution ultrasound at basal conditions (control) and under the effects of the drugs at the end of 8 and 16 weeks. Results Cholesterol and LDL cholesterol levels significantly decreased with simvastatin treatment alone or with enalapril. Mean baseline arterial diameter was 5.24 ± 1.25 mm in group 1 and 4.83 ± 0.99 mm in group 2 (not significant). In group 1 after the first 8 weeks, endothelium-dependent vasodilation significantly increased with simvastatin treatment (control, 4.4%; 8 weeks, 7.6%; P < .001). After 16 weeks with the addition of enalapril, a further increase in vasodilation was seen (8.6%, P < .05 vs 8 weeks). In group 2, with enalapril treatment an increase in vasodilation versus control was seen (control, 4.3%; 8 weeks, 5.8%; P < .01). After 16 weeks, with the addition of simvastatin an additional increase in vasodilation was observed (9.1%, P < .001 vs 8 weeks). After nitroglycerin, vasodilation in group 1 at control, 8, and 16 weeks was 17%, 17.5%, and 18%, respectively. In group 2, nitroglycerin vasodilation at control, 8, and 16 weeks was 21%, 21%, and 22%, respectively. Conclusions Simvastatin significantly increased the postischemic vasodilator response in patients with coronary hypercholesterolemia, either as single treatment or added to enalapril. Similarly, the response was increased by enalapril, either alone or while simvastatin was being administered. Both drugs improve vasodilation and additive effects appear to be present. (Am Heart J 2000;140:684-9.)</description><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brachial Artery - diagnostic imaging</subject><subject>Brachial Artery - drug effects</subject><subject>Brachial Artery - physiopathology</subject><subject>Cardiovascular system</subject><subject>Cholesterol - blood</subject><subject>Coronary Disease - blood</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - physiopathology</subject><subject>Cross-Over Studies</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Enalapril - therapeutic use</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Hypercholesterolemia - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Pharmacology. Drug treatments</subject><subject>Simvastatin - therapeutic use</subject><subject>Tropical medicine</subject><subject>Ultrasonography</subject><subject>Vasodilation - drug effects</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQhi0EotvCmRuyhMSpae3EGydHVJUPqRIXOFuOPVZcJXbwJEX7m_onmdWu4MRpPONnXnvmZeydFDdStPp2Hh9vaiGOWd-q_gXb0UFXrVbqJdvRRV11WjQX7BLxkdK27trX7EJKIWWj2h17vk8-ryNMcZsrDwskD2nlBXDJCQF5THyxa6Qi8t9xHfl4WKC4MU-AKxQKc3Tc5ZKTLQduCxUP3EcEi8A3kiuc9DmEAI40cuAY5yeLK6kmbpPnkOxklxKnaw70AjUgLLbYFaYDz4XE5yEm8G_Yq2AnhLfneMV-fr7_cfe1evj-5dvdp4fKNVquVTv0Sjaudk2rB6kGMXSiF070Pmga2tpGa9tK7-v9PnSqDn1onAM3qL2DoeuaK_bxpLuU_GujMc0c0cE02QR5Q6PrRqhWHMHbE-hKRiwQDE0x0xqMFObojyF_zNEfc_KHOt6fpbdhBv-PPxtCwIczYNHZKRSbXMS_nO76faeI6k8U0BqeIhSDjixy4GOhLRuf43-_8Ac24bEO</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>Esper, Ricardo J.</creator><creator>Machado, Rogelio</creator><creator>Vilariño, Jorge</creator><creator>Cacharrón, José L.</creator><creator>Ingino, Carlos A.</creator><creator>Garcı́a Guiñazú, Carlos A.</creator><creator>Bereziuk, Eulalio</creator><creator>Bolaño, Alberto L.</creator><creator>Suarez, Daniel H.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined</title><author>Esper, Ricardo J. ; Machado, Rogelio ; Vilariño, Jorge ; Cacharrón, José L. ; Ingino, Carlos A. ; Garcı́a Guiñazú, Carlos A. ; Bereziuk, Eulalio ; Bolaño, Alberto L. ; Suarez, Daniel H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-6b9413c2c367b14b0b8090c09df7134aa377a61dd255f842f9f3ccecb45ceb883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brachial Artery - diagnostic imaging</topic><topic>Brachial Artery - drug effects</topic><topic>Brachial Artery - physiopathology</topic><topic>Cardiovascular system</topic><topic>Cholesterol - blood</topic><topic>Coronary Disease - blood</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - physiopathology</topic><topic>Cross-Over Studies</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Enalapril - therapeutic use</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Hypercholesterolemia - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Pharmacology. Drug treatments</topic><topic>Simvastatin - therapeutic use</topic><topic>Tropical medicine</topic><topic>Ultrasonography</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Esper, Ricardo J.</creatorcontrib><creatorcontrib>Machado, Rogelio</creatorcontrib><creatorcontrib>Vilariño, Jorge</creatorcontrib><creatorcontrib>Cacharrón, José L.</creatorcontrib><creatorcontrib>Ingino, Carlos A.</creatorcontrib><creatorcontrib>Garcı́a Guiñazú, Carlos A.</creatorcontrib><creatorcontrib>Bereziuk, Eulalio</creatorcontrib><creatorcontrib>Bolaño, Alberto L.</creatorcontrib><creatorcontrib>Suarez, Daniel H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Esper, Ricardo J.</au><au>Machado, Rogelio</au><au>Vilariño, Jorge</au><au>Cacharrón, José L.</au><au>Ingino, Carlos A.</au><au>Garcı́a Guiñazú, Carlos A.</au><au>Bereziuk, Eulalio</au><au>Bolaño, Alberto L.</au><au>Suarez, Daniel H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>140</volume><issue>4</issue><spage>684</spage><epage>689</epage><pages>684-689</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background Endothelial dysfunction is an early event in atherosclerotic disease that precedes clinical manifestations and complications. The noninvasive assessment of endothelial function in patients with risk factors undergoing clinical treatment is an important medical advance. In this setting, altered endothelial function in patients with coronary hypercholesterolemia and its modifications by treatment with enalapril and simvastatin, either separately or in combination, was assessed in the brachial artery in a randomized, double-blind, 2-period crossover study. Methods Thirty-eight patients were separated in 2 groups. Group 1 (18 patients, 3 female, mean age 63 ± 6.0 years) received simvastatin 10 mg/d for 8 weeks and simvastatin plus enalapril 5 mg/d for another 8 weeks. Group 2 (20 patients, 3 female, mean age 64 ± 5.8 years) received enalapril 5 mg/d for 8 weeks and enalapril plus simvastatin 10 mg/d for another 8 weeks. All subjects underwent measurements of brachial artery diameter before and after postischemic hyperemia with high-resolution ultrasound at basal conditions (control) and under the effects of the drugs at the end of 8 and 16 weeks. Results Cholesterol and LDL cholesterol levels significantly decreased with simvastatin treatment alone or with enalapril. Mean baseline arterial diameter was 5.24 ± 1.25 mm in group 1 and 4.83 ± 0.99 mm in group 2 (not significant). In group 1 after the first 8 weeks, endothelium-dependent vasodilation significantly increased with simvastatin treatment (control, 4.4%; 8 weeks, 7.6%; P < .001). After 16 weeks with the addition of enalapril, a further increase in vasodilation was seen (8.6%, P < .05 vs 8 weeks). In group 2, with enalapril treatment an increase in vasodilation versus control was seen (control, 4.3%; 8 weeks, 5.8%; P < .01). After 16 weeks, with the addition of simvastatin an additional increase in vasodilation was observed (9.1%, P < .001 vs 8 weeks). After nitroglycerin, vasodilation in group 1 at control, 8, and 16 weeks was 17%, 17.5%, and 18%, respectively. In group 2, nitroglycerin vasodilation at control, 8, and 16 weeks was 21%, 21%, and 22%, respectively. Conclusions Simvastatin significantly increased the postischemic vasodilator response in patients with coronary hypercholesterolemia, either as single treatment or added to enalapril. Similarly, the response was increased by enalapril, either alone or while simvastatin was being administered. Both drugs improve vasodilation and additive effects appear to be present. (Am Heart J 2000;140:684-9.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>11011346</pmid><doi>10.1067/mhj.2000.109649</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 2000-10, Vol.140 (4), p.684-689 |
issn | 0002-8703 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_72304608 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biological and medical sciences Brachial Artery - diagnostic imaging Brachial Artery - drug effects Brachial Artery - physiopathology Cardiovascular system Cholesterol - blood Coronary Disease - blood Coronary Disease - drug therapy Coronary Disease - physiopathology Cross-Over Studies Double-Blind Method Drug Therapy, Combination Enalapril - therapeutic use Endothelium, Vascular - drug effects Endothelium, Vascular - physiopathology Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Hypercholesterolemia - physiopathology Male Medical sciences Middle Aged Miscellaneous Pharmacology. Drug treatments Simvastatin - therapeutic use Tropical medicine Ultrasonography Vasodilation - drug effects |
title | Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A39%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endothelium-dependent%20responses%20in%20patients%20with%20hypercholesterolemic%20coronary%20artery%20disease%20under%20the%20effects%20of%20simvastatin%20and%20enalapril,%20either%20separately%20or%20combined&rft.jtitle=The%20American%20heart%20journal&rft.au=Esper,%20Ricardo%20J.&rft.date=2000-10-01&rft.volume=140&rft.issue=4&rft.spage=684&rft.epage=689&rft.pages=684-689&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1067/mhj.2000.109649&rft_dat=%3Cproquest_cross%3E72304608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72304608&rft_id=info:pmid/11011346&rft_els_id=S0002870300163422&rfr_iscdi=true |